Drug ID:Drug168
Drug Name:VTX002
CID:129143185
DrugBank ID:NULL
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NCT05156125
Molecular Formula:C21H13Cl3F3N5O3
Molecular Weight:546.7 g/mol
Isomeric SMILES:C1CC(=O)NC[C@@H]1OC2=C(C=C(C(=C2)Cl)C3=NOC(=N3)C4=CN5C=C(C=C(C5=N4)Cl)C(F)(F)F)Cl
Synonyms:Tamuzimod; 2097854-81-2; (5R)-5-[2,5-dichloro-4-[5-[8-chloro-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]-1,2,4-oxadiazol-3-yl]phenoxy]piperidin-2-one; tamuzimod [INN]; Tamuzimod (USAN/INN); TAMUZIMOD [USAN]; K02SHW3KV9; VTX002; CHEMBL5314488; SCHEMBL18869627
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
No data available

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT05156125 VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING Oppilan Pharma Ltd Colitis, Ulcerative DRUG: VTX002|DRUG: VTX002|DRUG: Placebo Details
NCT05687474 Baby Detect : Genomic Newborn Screening NULL COMPLETED Centre Hospitalier Universitaire de Liege Congenital Adrenal Hyperplasia|Familial Hyperinsu… None Details
NCT05643534 Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years PHASE3 RECRUITING Ardelyx Irritable Bowel Syndrome With Constipation (IBS-C) DRUG: Tenapanor 50 MG|DRUG: Tenapanor 25 mg bid|D… Details
NCT05633706 Evaluation of the SIMBA Capsule for Small Intestinal Dysbiosis NULL RECRUITING Nimble Science Ltd. Irritable Bowel Syndrome|Crohn Disease|Celiac Dis… DEVICE: fluid biopsy capsule Details
NCT07168434 Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome PHASE3 RECRUITING Biocodex IBS (Irritable Bowel Syndrome)|IBS-D (Diarrhea-pr… DRUG: Saccharomyces Boulardii 250 MG|DRUG: Placeb… Details
NCT05602116 ASC - Autism Study PHASE1 COMPLETED Cell to Cure ApS Autism Spectrum Disorder|Gastrointestinal Dysfunc… DRUG: Adipose tissue derived mesenchymal stromal/… Details
NCT05588843 Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING Sanofi Colitis Ulcerative DRUG: SAR443122|DRUG: Placebo Details
NCT05573685 Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training NA COMPLETED Click Therapeutics, Inc. Rheumatoid Arthritis|Diabetic Neuropathy|Fibromya… DEVICE: DiNaMo Study App|DEVICE: Placebo App Details
NCT05536440 A Study to Learn About Study Medicine Called PF-07261271 in Healthy People PHASE1 COMPLETED Pfizer Healthy DRUG: PF-07261271|DRUG: Placebo Details
NCT05528510 A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis PHASE3 ACTIVE_NOT_RECRUITING Janssen Research & Development, LLC Colitis, Ulcerative DRUG: Guselkumab Dose 1|DRUG: Guselkumab Dose 2|D… Details
NCT07161297 Remimazolam for Colonoscopy in IBD Patients PHASE4 NOT_YET_RECRUITING Humanitas Clinical and Research Center IBD (Inflammatory Bowel Disease) DRUG: Intravenous remimazolam (5 mg initially, wi… Details
NCT05509777 A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease PHASE3 RECRUITING Eli Lilly and Company Crohn's Disease DRUG: Mirikizumab Details
NCT05507216 ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 PHASE3 COMPLETED Abivax S.A. Ulcerative Colitis DRUG: ABX464|DRUG: Placebo Details
NCT05466890 Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC) PHASE2 ACTIVE_NOT_RECRUITING Palatin Technologies, Inc Ulcerative Colitis|Ulcerative Colitis Acute|Ulcer… DRUG: PL8177 Placebo|DRUG: PL8177 Details
NCT05451433 The Effect of Saccharomyces Boulardii in Clinical Presentation and Quality of Life Patient With IBS NA UNKNOWN Fakultas Kedokteran Universitas Indonesia Irritable Bowel Syndrome DRUG: Saccharomyces Boulardii 250 MG|DRUG: Placebo Details
NCT05377580 A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis PHASE2 COMPLETED Innovent Biologics (Suzhou) Co. Ltd. Ulcerative Colitis (UC) DRUG: Period 1 IBI112 Placebo|DRUG: Period 2 IBI1… Details
NCT05370885 VE202 in Patients With Mild-to-Moderate Ulcerative Colitis PHASE2 TERMINATED Vedanta Biosciences, Inc. Ulcerative Colitis|Colitis, Ulcerative BIOLOGICAL: VE202|DRUG: Vancomycin Oral Capsule|O… Details
NCT07145580 Combined Lactulose H2-breath Test With Abdominal Imaging NULL RECRUITING Klinik Arlesheim Food Intolerance Syndromes|Small Intestinal Bacte… None Details
NCT05291689 A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC PHASE2 COMPLETED Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) Inflammatory Bowel Diseases|Colitis, Ulcerative DRUG: MORF-057 Details
NCT05271838 Protein and Magnesium in Ulcerative Colitis NA UNKNOWN University of Aarhus Inflammatory Bowel Diseases|Colitis, Ulcerative|M… DIETARY_SUPPLEMENT: Magnesium acetate mixture (30… Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S07 Blockade of cytokine Cytokine signalling apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab Various T-cell subsets, their differentiation pathways and … Details

Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a …

PMID: 39793589
Year: 2025
Relationship Type: Treatment Score: 6.5

BACKGROUND: Tamuzimod (VTX002) is a selective sphingosine 1-phosphate receptor 1 modulator in development for ulcerative colitis. We aimed to assess …

View Details